Head-to-head evidence
fluticasone furoate/vilanterol vs indacaterol maleate / mometasone furoate
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Asthma
Shared mechanism: Glucocorticoid receptor / Beta-2 adrenergic receptor · full Asthma pipeline
fluticasone furoate/vilanterol
Marketed by GlaxoSmithKline
NCT01086384 · Phase 3 · completed
This was a randomized, triple-blind, active-controlled trial with approximately 2,019 treated participants. Its primary hard clinical endpoint—having one or more severe asthma exacerbations—favored fluticasone furoate/vilanterol and was statistically significant.
indacaterol maleate / mometasone furoate
Developed by Novartis
NCT00557440 · Phase 2 · completed
The study was randomized and quadruple-blind, used both placebo and active control, and measured the clinically relevant lung-function endpoint FEV1. Although the primary comparison favored indacaterol/mometasone over placebo and was statistically significant, the small sample of 37 participants limits the strength of the evidence.
Next expected readout: February 2028 · NCT05562466 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: fluticasone furoate/vilanterol's landscape · indacaterol maleate / mometasone furoate's landscape